Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Martin Huličiak Supervisor: PharmDr. Lukáš Červený, Ph.D Title of diploma thesis: Study of interactions of antiviral drugs with intestinal drug efflux ABC transporters P-gp, MRP2 and BCRP are efflux transporters, members of the family of ATP binding cassette (ABC) transporters. These transporters are located on the apical membrane of the intestinal epithelium, where they may limit absorption of orally administered drugs. Study of drug interactions with/on intestinal efflux transporters is necessary to provide safe and effective treatment. The Caco-2 cell line is FDA recommended in vitro model of intestinal barrier and it is used for bidirectional testing of substrates and inhibitors of ABC transporters in preclinical research. However, this methodology has several shortcomings, so the need of introduction of new experimental models is increasing and the ex vivo method based on human or rat intestine is a promising option. Precision-cut intestinal slices (PCIS) represent a mini-model of the organ and contain all types of cells of the tissue. We used both in vitro model using Caco-2 cell monolayers for drug transport study and in our lab established ex vivo method of PCIS for accumulation study...

Produtos de glicação avançada (AGE) prejudicam o metabolismo de lipoproteínas e o transporte reverso de colesterol, o que contribui para a aterosclerose no diabete melito (DM). Em particular, a albumina modificada por AGE (albumina-AGE) reduz a remoção de colesterol por diminuir o conteúdo do receptor ABCA-1 em macrófagos. Isto se vincula ao insulto oxidativo e inflamatório, os quais são indutores do estresse do retículo endoplasmático (RE). O objetivo do presente estudo foi avaliar, em macrófagos, os efeitos do tratamento com albumina-AGE sobre o estresse do RE e suas vias adaptativas (UPR), relacionando-os com o prejuízo na expressão do ABCA-1 e efluxo de colesterol celular. Albumina-AGE foi produzida pela incubação de albumina isenta em ácidos graxos com glicolaldeído 10 mM e, albumina controle (albumina-C) com PBS apenas. Albumina foi isolada do soro de pacientes portadores de DM com controle glicêmico inadequado (albumina-DM) ou indivíduos controles (albumina não- DM) por cromatografia para separação rápida de proteínas seguida por purificação alcoólica. Macrófagos de peritônio de camundongos ou macrófagos da linhagem J774 foram tratados com os diferentes tipos de albumina na presença ou ausência de ácido fenil butírico (PBA; chaperona química que alivia o estresse do RE) ou MG-132 (inibidor do sistema proteasomal) por diferentes intervalos de tempo. A expressão de marcadores do estresse do RE, UPR, proteína dissulfeto isomerase (PDI), calreticulina e ubiquitina foi determinada por imunoblot e o conteúdo de ABCA-1, por citometria de fluxo e imunocitoquímica. O efluxo de 14Ccolesterol foi avaliado, utilizando-se apoA-I como aceptora de colesterol. A albumina-AGE induziu aumento tempo-dependente na expressão das chaperonas marcadoras do estresse do RE - Gr78 e Grp94 - e de proteínas da UPR (ATF6 e eIF2-P) em comparação à albumina-C. O conteúdo de ABCA-1 e o efluxo de colesterol foram reduzidos em, respectivamente, 33% e 47% e ambos foram restaurados pelo tratamento com PBA, o qual também reduziu o estresse do RE. A associação entre estresse de RE e redução de ABCA-1 foi confirmada pelo uso da tunicamicina (indutor clássico de estresse do RE), que diminuiu em 61% o conteúdo de ABCA-1, prejudicando em 82% o efluxo de colesterol. A albumina-AGE aumentou o conteúdo total de ubiquitina. A inibição do sistema proteasomal não foi capaz de restaurar o conteúdo de ABCA-1 em células tratadas com albumina-AGE. Em macrófagos expostos à albumina-DM evidenciou-se maior expressão da PDI e calreticulina, com tendência à maior expressão da Grp94. A albumina-AGE (produzida in vitro ou isolada de portadores de DM) induz estresse de RE, o qual se vincula à redução no conteúdo de ABCA-1 e efluxo de colesterol. Estes eventos podem contribuir para a aterosclerose no DM. Chaperonas químicas, que aliviam o estresse do RE, podem ser ferramentas úteis na prevenção e tratamento da aterosclerose / Advanced glycation end products (AGE) disturb lipoprotein metabolism and reverse cholesterol transport, contributing to atherosclerosis in diabetes mellitus (DM). Particularly, advanced glycated albumin (AGE-albumin) reduces cell cholesterol removal by impairing the expression of ABCA-1 in macrophages. This is ascribed to the oxidative and inflammatory stress, conditions that elicit endoplasmic reticulum (ER) stress. In this study it was investigated the effect of AGE-albumin on ER stress and adaptative pathways (UPR) development in macrophages, and its relationship to the reduction in ABCA-1 expression and cholesterol efflux. AGE-albumin was prepared by incubating fatty acid free albumin with 10 mM glycolaldehyde and control albumin (C-albumin) with PBS only. Albumin was isolated from poorly controlled DM patients (DM-albumin) and control individuals (nonDMalbumin) by fast liquid chromatography and purified by alchoolic extraction. Mouse peritoneal macrophages or J774 cells were treated along time with the different types of albumin in the absence or presence of phenyl butiric acic (PBA; a chaperone that aleviates ER stress) or MG132 (a proteasomal inhibitor). The expression of ER stress and UPR markers, protein disulfide isomerase (PDI), calreticulin and ubiquitin was determined by immunoblot and ABCA-1 protein level, by flow cytometry and imunocytochemistry. 14Ccholesterol efflux was evaluated utilizing apo A-I as cholesterol acceptor. AGE-albumin induced a time-dependent increase in the expression of ER stress chaperone markers - Gr78 and Grp94 - and UPR proteins (ATF6 and eIF2-P) in comparison to C-albumin. ABCA-1 content and cholesterol efflux were diminished by, respectively, 33% and 47% and both were recovered by the treatment with PBA. The association between ER stress and ABCA-1 reduction was confirmed by the reduction, induced by tunicanycin (a classical ER stress inductior) in ABCA-1 protein level (61%) and cholesterol efflux (82%). AGE-albumin increased the amount of cellular total ubiquitin. The inhibiton of proteasomal system was unable to restore ABCA-1 protein level in cells treated with AGE-albumin. In macrophages exposed to DM-albumin a higher expression of PDI and calreticulin was observed together with a trend of enhanced Grp94 expression. In conclusion, AGE-albumin (produced in vitro or isolated from DM patients) induces ER stress which is related to the reduction in ABCA-1 level and cholesterol efflux in macrophages. These events can contribute to atherosclerosis in DM. Chemical chaperones that alleviate ER stress may be useful in the prevention and treatment of atherosclerosis

Protein Vga(A) gives staphylococci resistance to streptogramins A. The recently discovered protein Vga(A)LC differs from Vga(A) only by 7 amino acid residues, but this difference is sufficient for shift of its substrate specificity towards lincosamides. The group of four amino acids in the central part of protein (LGAG in Vga(A) and SVTS in Vga(A)LC) was detected to be crucial for the substrate specificity. In this diploma thesis 5 alternativesets of vga(A)LC gene point mutations were prepared in order to determine the impact of individual amino acids of the aforementioned group on the resistance phenotype. Mutations were prepared in vector pGEM® -T and cloned into shuttle vector pRB374. The prepared constructs were transformed by electroporation into the sensitive strain of Staphylococcus aureus RN4220 and values of minimum inhibitory concentration (MIC) were measured for lincomycin, clindamycin and pristinamycin IIA by the agar dilution method. The transformation was not successful in one of the mutations. Results of setting MIC for the remaining four mutations do not make it possible to specify uniquely the ratio of individual amino acids for determining substrate specificity. Two of the amino acids were found to be important. We anticipate preparation of more mutations.

Flax (Linum usitatissimum L.) is a self-pollinated crop widely cultivated for fiber and oil production. Flaxseed is renowned for its health attributes but the presence of compounds, such as the heavy metal cadmium (Cd), is undesirable. Genomic studies in flax have produced large amounts of data in the last 15 years, providing useful resources to improve the genetic of this crop using genomics-based technologies and strategies. The goal of this thesis is therefore to capitalize on these advances to address the Cd problem and to propose solutions to improve breeding efficiencies. To find genomic-based solutions to Cd content, to the currently low breeding efficiency and to abiotic stress resistance in flax, this study utilized four major strategies: (1) genomic cross prediction, (2) gene family identification, (3) genome-wide association study (GWAS) and (4) genomic selection (GS). Characterization of the ATP-binding cassette (ABC) transporter and heavy metal associated (HMA) gene families was performed using the flax genome sequence. A total of 198 ABC transporter and 12 HMA genes were identified in the flax genome, of which nine were orthologous to Cd-associated genes in Arabidopsis, rice and maize. A transcriptomic analysis of eight tissues provided some support towards the functional annotation of these genes and confirmed the expression of these ABC transporter and HMA genes in flax seeds and other tissues. A diversity panel of 168 flax accessions was grown in the field at multiple locations and years and the seed content of 24 heavy metals (HMs) was measured. The panel was also sequenced and a single nucleotide polymorphism (SNP) dataset of nearly 43,000 SNPs was defined. A GWAS was conducted using these genotypic and phenotypic data and a total of 355 non-redundant quantitative trait nucleotides (QTNs) were identified for ten of the 24 metal contents. Overall, a total of 24 major and 331 minor effect QTNs were detected, including 11 that were pleiotropic. After allelic tests, 108 non-redundant QTNs were retained for eight of the ten metals and ranging from one for copper (Cu) to 70 for strontium (Sr). A total of 20 candidate genes for HM accumulation were identified at 12 of the 24 major QTN loci, of which five belonged to the ABC transporter family. Many of the metal contents, including Cd, appeared to be controlled by many genes of small effects; hence, GS is better suited than marker-assisted selection for application in breeding. To test this, predictive ability using ten GS statistical models was evaluated using trait-specific QTN and the random genome-wide 43K SNP datasets. Significantly higher predictive abilities were observed from the GS models built with the dataset made of QTNs associated with metal contents (70-80%) compared to that of the 43K dataset (10-25%). This study showed the feasibility of using GS to improve the predictive ability of polygenic traits such as metal content in seeds. GS can be applied in early generation selection to accelerate the improvement of abiotic stress resistance and either select low-Cd lines or discard high-Cd lines. These findings validate the use of a QTL-based strategy as a highly effective method for improving the efficiency of predictive ability of GS for highly complex traits such as resistance or tolerance to HM accumulation. Identification of both large and minor effect QTNs and/or pleiotropic effects hold potential for flax breeding improvement. Candidate gene functional validation can be performed using methods such as genome editing or targeting induced local lesions in genomes (TILLING).

La résistance aux lactones macrocycliques (LM) constitue une préoccupation croissante dans le contrôle des nématodes parasitaires, notamment l'Haemonchus contortus chez les ruminants. Parmi les mécanismes étudiés dans la résistance aux LM chez les nématodes d’importance en santé animale, il y a les pompes ABC, principalement les glycoprotéines-p, connues pour leur rôle dans la détoxification des LM chez les strongles. Il n'existe toutefois aucune étude sur l'extrusion des lipides par les pompes ABC en tant que produits excrétoires/sécrétoires provenant d'H. contortus (Hc-PES). Nous émettons l’hypothèse que les pompes ABC chez H. contortus sont à la fois impliquées dans l’extrusion de LM (contribuant à la résistance aux antihelminthiques) et dans l’efflux de lipides secrétés par le parasite. Notre objectif était de caractériser le rôle des pompes ABC chez H. contortus dans le contexte de la résistance aux LM et de l'extrusion des lipides. L'efficacité de l'ivermectine, un membre de LM, a été évaluée dans 8 fermes étudiées par un test de réduction de la numération des œufs dans les selles (TRNOS). Les niveaux d'expression des pompes ABC ont été évalués dans des isolats de champ d’H. contortus avec des résultats TRNOS faibles (présumé souches résistantes). D’ailleurs, des vers adultes d’H. contortus ont été incubés avec trois inhibiteurs de pompes ABC, dont le Fumitremorgin C, le Kétoconazole et le Mk-571 à concentrations différentes. Les lipides ont été identifiés par CL/SM dans les milieux de culture récupérés à 2 h, à 4 h et à 8 h après l'incubation d’H. contortus dans les groupes contrôle et traités. L'expression des gènes Hco-pgp-2 et Hco-pgp-3 était augmentée chez les isolats de champ d’H. contortus. Nous avons identifié 1045 lipides appartenant à diverses catégories. L'extrusion des lipides en Hc-PES a changé en présence d'inhibiteurs de pompes ABC, en particulier pour les lipides composés de structures correspondant à celles pour le transport par les pompes ABC. Nous avons donc conclu que les pompes ABC chez H. contortus représentent un système de multi-extrusion et sont impliquées dans la sécrétion de lipides avec importance dans l’interaction avec l’hôte, mais aussi dans la résistance aux LM chez le nématode. / Macrocyclic lactones (MLs) resistance is a growing concern in controlling parasitic nematodes, particularly Haemonchus contortus in the ruminants’ industry. ABC transporters are known to participate in translocating various lipophilic molecules, including MLs and lipids. Some ABC transporters, mostly P-glycoproteins are known to be involved in MLs detoxification in parasitic nematodes; but there is no data about extrusion of lipids by ABC transporters as Excretory/Secretory Products in H. contortus (Hc-ESP). We hypothesize that ABC transporters in H. contortus have a dual role participating in the efflux of MLs, thus contributing to anthelmintic resistance, and in the extrusion of lipids out of the parasite. This study aimed to characterize the role of H. contortus ABC transporters in the context of ML resistance and the extrusion of lipids. Ivermectin (a member of MLs) efficacy was evaluated in 8 studied farms by the fecal egg count reduction test (FECRT). The expression levels of ABC transporters were evaluated in field isolates of H. contortus with low FECRT results (suspected of resistance). H. contortus adult worms were incubated with three ABC inhibitors, such as Fumitremorgin C, Ketoconazole and Mk-571 with different concentrations. Lipids were identified by LC/MS in culture media at 2h, 4h and 8h post incubation with H. contortus in control and treated groups. Hco-pgp-2 and Hco-pgp-3 were found upregulated in H. contortus field isolates. We identified 1045 lipid molecules belonging to different categories. Interestingly, the lipid profile in Hc-ESP was altered in the presence of ABC transporter inhibitors, which shows structural features compatible as substrates for nematode transporters’ activity. Therefore, ABC transporters in H. contortus participate in extrusion of lipids and also may help in detoxification of MLs, becoming a multipurpose pumping system involved in ML resistance and secretion of lipids at the interplay with the host and among nematodes.

L’échec thérapeutique des maladies cérébrales est lié, entre autres, à la présence de barrières entre le sang et le Système Nerveux Central (SNC), en particulier la Barrière Hémato-Encéphalique (BHE). La BHE est une structure neuro-vasculaire localisée au niveau des MicroVaisseaux Cérébraux (MVC) limitant l’entrée des molécules thérapeutiques dans le cerveau. Ce rôle barrière est dû à plusieurs facteurs, dont principalement, l’existence du côté luminal et/ou abluminal de la BHE de plusieurs transporteurs d’efflux, dont les transporteurs de type ABC (ATP Binding Casette) et SLC (SoLute Carrier) et qui sont à l’origine des phénomènes de résistance aux médicaments. Les études de recherche actuelles visent à identifier les voies de signalisation régulant l’activité de ces protéines d’efflux afin d’optimiser la pharmacothérapie cérébrale. Mais la majorité de ces études sont effectuées chez l’adulte. Très peu de données existent chez l’enfant.Cette étude a été réalisé dans la perspective de 1) Etudier l’ontogenèse des transporteurs ABC et SLC de la BHE au cours de la maturation cérébrale, 2) Elucider le rôle fonctionnel de quatre transporteurs d’efflux ((P-glycoproteine (P-gp), Breast Cancer Resistance Protein (bcrp), Organic Anion Transporter 3 (oat3), and Transporting Peptide 1a4 (oatp1a4) transporters) dans le cerveau des enfants et 3) Elucider les mécanismes qui régulent leur expression fonctionnelle dans des conditions normales et pathologiques, notamment inflammatoires, parce que des modifications dans les composantes structurales et fonctionnelles de l'unité neurovasculaire ont été rapportées dans une longue liste de pathologies du SNC chez les enfants et les adultes. Nos résultats ont montré l’existence de différences fonctionnelles, en terme de passage de molécules, entre la BHE pédiatrique et celle adulte. De plus, cette étude a mis en évidence une régulation différentielle liée à l'âge des transporteurs d'efflux de médicaments de la barrière dans des conditions normales et inflammatoires.Ces résultats fournissent des preuves sur l’intérêt de prendre en compte les propriétés spécifiques de la BHE pédiatrique et la distinguer de la BHE adulte lors des définitions des stratégies thérapeutiques destinées à traiter les maladies cérébrales chez les enfants. / One major reason of CNS pharmacotherapy’s impediment is the existence of “barriers” between blood and CNS, especially the Blood-Brain Barrier (BBB), a neurovascular structure localized at the level of brain microvasculature. Main factors responsible for this barrier function are drug efflux transporters type ABC (ATP-Binding Cassette) and SLC (SoLute Carrier) expressed at BBB level and known to be at the origin of multi-drug resistance phenomenon. Recent researches aim at unraveling the signaling mechanisms regulating these transporters in order to modulate their activity and improve pharmacotherapy in brain diseases. For years, these transporters have been studied in adult organism. But, there is a wide spread belief that the BBB in embryo, fetus, new born and infant is “immature”, implying caution in giving drugs to infants. However, current knowledge on the functional status of the BBB in immature organism remains very limited.This study was performed in the aim of understanding: 1) The ontogenesis of ABC and SLC transporters during brain maturation, 2) the functional role of four BBB drug efflux transporters (P-glycoprotein (P-gp), Breast Cancer Resistance Protein (bcrp), Organic Anion Transporter 3 (oat3), and Transporting Peptide 1a4 (oatp1a4) transporters) in children’s brain, and 3) the mechanisms that regulate their functional expression under normal and pathological conditions, mostly under inflammatory conditions, because indeed alterations in structural and functional components of the BBB have been reported in a long list of CNS pathologies in adults. Our results showed changing properties of the BBB during ontogenesis, as well as an age-related differential regulation of BBB drug efflux transporters under normal and inflammatory conditions.These findings highlight the importance of considering an age-related response of CNS to drugs and of taking into account the specific properties of juvenile BBB during definition of therapeutic strategies designed to treat childhood brain diseases, and this in the clinical perspective of developing new drugs with enhanced efficacy in children’s CNS.

Les pyréthrinoïdes et les organophosphorés sont des pesticides très utilisés, à l’origine d’une imprégnation forte de la population, exposée à ces contaminants principalement via l’alimentation. De plus en plus d’études scientifiques suggèrent des liens entre l’exposition à ces composés et des maladies chroniques ou des troubles du développement de l’enfant. Paradoxalement, leur devenir biologique chez l’homme est mal connu. Certaines études suggèrent que ces insecticides sont susceptibles d’intéragir avec les transporteurs membranaires ABC et SLC, protéines localisées au niveau d’interfaces hémato-tissulaires qui prennent en charge de nombreux substrats endogènes, médicaments et contaminants de l’environnement. L’objectif de notre étude a été de caractériser les effets d’insecticides des familles des pyréthrinoïdes et des organophosphorés sur l’activité de nombreux transporteurs ABC et SLC prenant en charge des médicaments (P-gp, BCRP, MRPs, OATP-1B1,-2B1,-1B3, OCT1-3, OAT1, OAT3, MATE1 et MATE2K) par une approche in vitro. Nous nous sommes également attachés à caractériser par des expérimentations in vitro et in silico, les mécanismes des interactions et les éléments structuraux des pesticides à l’origine de ces effets. Nous avons montré que de nombreux organophosphorés et pyréthrinoïdes étaient capables d’inhiber des transporteurs d’efflux (MRP, BCRP, P-gp) et d’influx (OATP1B1, OAT3, MATE1, OCT1-2) et de stimuler l’activité de certains OATPs. Les pesticides testés inhibaient très fortement l’activité des transporteurs de cations (OCT1 et OCT2) et ont pu bloquer le transport de catécholamines médiés par ces protéines. Une approche qSAR a permis de définir des paramètres physicochimiques associés aux effets modulateurs des pesticides et une approche d’amarrage moléculaire (docking) a mise en évidence les sites de liaisons de la P-gp impliquées dans ces interactions. Les conséquences des modulations de l’activité des transporteurs, en termes d’effets toxiques et d’interactions médicamenteuses, restent à définir pour les populations exposées à de fortes doses de pesticides. Toutefois, la contribution des interactions observées aux effets toxiques de ces insecticides est peu probable car nécessitant des concentrations nettement supérieures à celles atteintes dans le cadre d’une exposition environnementale de la population générale. / The general population is chronically exposed to pyrethroids and organophosphorus insecticides, mainly through alimentation. Several epidemiological studies have found an association between non-occupational exposure to these pesticides and chronic diseases and developmental disorders. Paradoxically, their biological fate in humans is poorly understood. Some studies suggest that these insecticides could interact with ABC and SLC membrane transporters. These membrane proteins, located at blood-tissue interfaces (liver, kidney, intestine ...), handle many endogenous substrates, drugs and pollutants. The objective of our study was to characterize, using an in vitro approach, the effects of pyrethroid and organophosphorus insecticides on the activity of numerous ABC and SLC human drug-transporters (P-gp, BCRP, MRPs, OATP-1B1, -2B1, -1B3, OCT1-3, OAT1, OAT3, MATE1 and MATE2K). We have also tried to analyze the mechanisms of interactions and the structural requirements for insecticides-mediated modulation of drug transporters activities using in vitro and in silico approach. We have shown that many organophosphorus and pyrethroids are able to inhibit ABC (MRP, BCRP, P-gp) and SLC (OATP1B1, OAT3, MATE1, OCT1-2) transporters and can stimulate the activity of some OATPs. Moreover, the tested pesticides inhibited very strongly the activity of OCT1 and OCT2 and blocked catecholamine transport mediated by these transporters. A qSAR approach allowed to define physicochemical parameters associated with the modulating effects of pesticides and a molecular docking approach revealed the P-gp binding sites involved in these interactions. The consequences of transporter activitie modulation, in terms of toxic effects and drug interactions, remain to be defined for populations exposed to high doses of pesticides, occurring notably in response to poisoning. However the alterations of these transporter activities by insecticides are unlikely to contribute to organophosphorus or pyrethroids toxicities of chronic low-dose exposure.

Glycosphingolipid (GSL) metabolism is a complex process involving proteins and enzymes at distinct locations within the cell. Mammalian GSLs are typically based on glucose or galactose, forming glucosylceramide (GlcCer) and galactosylceramide (GalCer). Most GSLs are derived from GlcCer, which is synthesized on the cytosolic leaflet of the Golgi, while all subsequent GSLs are synthesized on the lumenal side. We have utilized both pharamacological and genetic manipulation approaches to selectively regulate GSL metabolism and better understand its mechanistic details. We have developed analogues of GlcCer and GalCer by substituting the fatty acid moiety with an adamanatane frame. The resulting adamantylGSLs are more water-soluble than their natural counterparts. These analogues selectively interfere with GSL metabolism at particular points within the metabolic pathway. At 40 µM, adaGlcCer prevents synthesis of all GSLs downstream of GlcCer, while also elevating GlcCer levels, by inhibiting lactosylceramide (LacCer) synthase and glucocerebrosidase, respectively. AdaGalCer specifically reduces synthesis of globotriaosylceramide (Gb3) and downstream globo-series GSLs. AdaGalCer also increases Gaucher disease N370S glucocerebrosidase expression, lysosomal localization and activity. AdaGSLs, therefore, have potential as novel therapeutic agents in diseases characterized by GSL anomalies and as tools to study the effects of GSL modulation. Two predominant theories have been developed to explain how GlcCer accesses the Golgi lumen: one involving direct translocation from the cytosolic-to-lumenal leaflet of the Golgi by the ABC transporter P-glycoprotein (P-gp, ABCB1, MDR1), and the other involving retrograde transport of GlcCer by FAPP2 to the ER, followed by entry into the vesicular transport system for Golgi lumenal access. To examine the in vivo involvement of P-gp in GSL metabolism, we generated a knockout model by crossbreeding the Fabry disease mouse with the P-gp knockout mouse. HPLC analyses of tissue Gb3 levels revealed a tissue-specific reduction in MDR1/Fabry mice. TLC analyses, however, did not show such reduction. In addition, we performed a gene knockdown study using siRNA against P-gp and FAPP2. Results show these siRNA to have distinct effects on GSL levels that are cell-type specific. These results give rise to the prospect of unique therapeutic approaches by targeting P-gp or FAPP2 for synthesis inhibition of particular GSL pathways.

Glycosphingolipid (GSL) metabolism is a complex process involving proteins and enzymes at distinct locations within the cell. Mammalian GSLs are typically based on glucose or galactose, forming glucosylceramide (GlcCer) and galactosylceramide (GalCer). Most GSLs are derived from GlcCer, which is synthesized on the cytosolic leaflet of the Golgi, while all subsequent GSLs are synthesized on the lumenal side. We have utilized both pharamacological and genetic manipulation approaches to selectively regulate GSL metabolism and better understand its mechanistic details. We have developed analogues of GlcCer and GalCer by substituting the fatty acid moiety with an adamanatane frame. The resulting adamantylGSLs are more water-soluble than their natural counterparts. These analogues selectively interfere with GSL metabolism at particular points within the metabolic pathway. At 40 µM, adaGlcCer prevents synthesis of all GSLs downstream of GlcCer, while also elevating GlcCer levels, by inhibiting lactosylceramide (LacCer) synthase and glucocerebrosidase, respectively. AdaGalCer specifically reduces synthesis of globotriaosylceramide (Gb3) and downstream globo-series GSLs. AdaGalCer also increases Gaucher disease N370S glucocerebrosidase expression, lysosomal localization and activity. AdaGSLs, therefore, have potential as novel therapeutic agents in diseases characterized by GSL anomalies and as tools to study the effects of GSL modulation. Two predominant theories have been developed to explain how GlcCer accesses the Golgi lumen: one involving direct translocation from the cytosolic-to-lumenal leaflet of the Golgi by the ABC transporter P-glycoprotein (P-gp, ABCB1, MDR1), and the other involving retrograde transport of GlcCer by FAPP2 to the ER, followed by entry into the vesicular transport system for Golgi lumenal access. To examine the in vivo involvement of P-gp in GSL metabolism, we generated a knockout model by crossbreeding the Fabry disease mouse with the P-gp knockout mouse. HPLC analyses of tissue Gb3 levels revealed a tissue-specific reduction in MDR1/Fabry mice. TLC analyses, however, did not show such reduction. In addition, we performed a gene knockdown study using siRNA against P-gp and FAPP2. Results show these siRNA to have distinct effects on GSL levels that are cell-type specific. These results give rise to the prospect of unique therapeutic approaches by targeting P-gp or FAPP2 for synthesis inhibition of particular GSL pathways.